NCT06416501

Brief Summary

This study aims to investigate the pathological characteristics and surgical outcomes of stage III CRC patients detected through screening. Data extracted from the database included the following patient information: age at diagnosis, gender, tumor location, neoadjuvant therapy, surgical procedures, histologic type, differentiation, vascular invasion, perineural invasion, pathological T stage, pathological N stage, and survival outcomes.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
4,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 9, 2024

Completed
2 days until next milestone

Study Start

First participant enrolled

May 11, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 16, 2024

Completed
16 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2024

Completed
Last Updated

May 16, 2024

Status Verified

May 1, 2024

Enrollment Period

21 days

First QC Date

May 9, 2024

Last Update Submit

May 15, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • overall survival

    The duration from the initial treatment to either death from any cause or the last recorded follow-up, whichever came first. Assessed up to 100 months.

    the duration from the initial treatment to either death from any cause or the last recorded follow-up, whichever came first. Assessed up to 100 months.

Study Arms (2)

screening

Patients who were detected through any screening test were categorized into the screening group

Other: Mode of detection

nonscreening

Patients who were detected based on symptoms formed the non-screening group.

Interventions

Mode of detection

screening

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients who underwent surgical intervention for CRC at Fudan University Shanghai Cancer Center.

You may qualify if:

  • Patients who underwent radical surgery for CRC, had confirmed stage III CRC through postoperative pathology, had no prior history of cancer before surgery, and had clear cancer detection information.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xinxiang Li

Shanghai, Shanghai Municipality, 200032, China

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

May 9, 2024

First Posted

May 16, 2024

Study Start

May 11, 2024

Primary Completion

June 1, 2024

Study Completion

June 15, 2024

Last Updated

May 16, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will share

Locations